Overcoming the memory barrier in tolerance induction: Molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 405-410

  Ford, Mandy L ^a   Larsen, Christian P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

costimulation; memory T cell; molecular mimicry; transplant

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GRANZYME B; HISTOCOMPATIBILITY ANTIGEN; LEUKOCYTE ANTIGEN; PERFORIN; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ANTIGEN;

ALLOIMMUNITY; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CELL COMPARTMENTALIZATION; CELL HETEROGENEITY; CELL POPULATION; CELLULAR IMMUNITY; CROSS REACTION; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HERPES VIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOLECULAR MIMICRY; NONHUMAN; ORGAN TRANSPLANTATION; PERIPHERAL T CELL LYMPHOMA; PRE T LYMPHOCYTE; REVIEW; SEQUENCE HOMOLOGY; TRANSPLANTATION TOLERANCE; VIRUS ATTENUATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

ANIMALS; ANTIGENS, VIRAL; CROSS REACTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR MIMICRY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION TOLERANCE; VIRUS DISEASES;

EID: 77955228981     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833b7916     Document Type: Review

References (44)

1. Lechler R, Batchelor R, Lombardi G. The relationship between MHC restricted and allospecific T cell recognition. Immunol Lett 1991; 29:41-50.
2. Lombardi G, Sidhu S, Daly M, et al. Are primary alloresponses truly primary? Int Immunol 1990; 2:9-13.
3. Macedo C, Orkis EA, Popescu I, et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009; 9:2057-2066.
4. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004; 4:846-852.
5. Ford ML, Kirk AD, Larsen CP. Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. Transplantation 2009; 87:S69-74.
6. Patel SR, Cadwell CM, Medford A, Zimring JC. Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. J Clin Invest 2009; 119:2787-2794.
7. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994; 179:1155-1161.
8. Burrows SR, Silins SL, Moss DJ, et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 1995; 182:1703-1715.
9. Burrows SR, Silins SL, Khanna R, et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 1997; 27:1726-1736.
10. Umetsu DT, Yunis EJ, Matsui Y, et al. HLA-DR-4-associated alloreactivity of an HLA-DR-3-restricted human tetanus toxoid-specific T cell clone: inhibition of both reactivities by an alloantiserum. Eur J Immunol 1985; 15:356-361.
11. Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood 2002; 99:3844-3847.
12. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T-cells is common. Blood 2010; 115:3146-3157.
13. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196:147-160.
14. Selin LK, Brehm MA, Naumov YN, et al. Memory of mice and men: CD8+ Tcell cross-reactivity and heterologous immunity. Immunol Rev 2006; 211:164-181.
15. Felix NJ, Donemeyer DL, Horvath S, et al. T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8:942-953.
16. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007; 7:942-953.
17. Macdonald WA, Chen Z, Gras S, et al. T cell allorecognition via molecular mimicry. Immunity 2009; 31:897-908.
18. Beddoe T, Chen Z, Clements CS, et al. Antigen ligation triggers a conformational change within the constant domain of the alphabeta T cell receptor. Immunity 2009; 30:777-788.
19. Sourdive DJ, Murali-Krishna K, Altman JD, et al. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med 1998; 188:71-82.
20. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, et al. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006; 108:3121-3127.
21. Ford ML, Floyd TL, Wagener ME, et al. Impact of donor-reactive precursor frequency on the differentiation of costimulation independent CD8+ memory T cells. Am J Transplant 2009; 9:333.
22. Ford ML, Wagener ME, Hanna SS, et al. A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection. J Immunol 2008; 180:7203-7211.
23. Koehn BH, Ford ML, Ferrer IR, et al. PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J Immunol 2008; 181:5313-5322.
24. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763.
25. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 2006; 177:831-839.
26. Amyes E, Hatton C, Montamat-Sicotte D, et al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003; 198:903-911.
27. Obhrai JS, Oberbarnscheidt MH, Hand TW, et al. Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol 2006; 176:4051-4058.
28. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887-1895.
29. Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82:1-9.
30. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92.
31. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465-474.
32. Schenk AD, Nozaki T, Rabant M, et al. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8:1652-1661.
33. Liu L, Zhong Q, Tian T, et al. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010; 16:224-227.
34. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258.
35. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15:746-749.
36. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453.
37. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
38. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
39. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
40. Pantenburg B, Heinzel F, Das L, et al. T cells primed by leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002; 169:3686-3693.
41. Setoguchi K, Schenk A, Ishii D, et al. Anti-lymphocyte function-associated antigen-1 (LFA-1) monoclonal antibody prevents graft-infiltrating CD8 memory T cells early post-transplant. Am J Transplant 2009; 9:209.
42. Ford ML, Steeds CM, Wagener ME, et al. Anti-LFA-1 Synergizes with CD28/ CD154 Blockade To Inhibit Anti-Donor Cytotoxicity and Promote Graft Survival in Recipients Possessing Donor-Reactive Memory T Cells. Am J Transplant 2010; 10 (s2):9.
43. Schenk AD, Gorbacheva V, Rabant M, et al. Effector functions of donorreactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant 2009; 9:64-73.
44. Kim JS, Lee JI, Shin JY, et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in nonhuman primates. Transplantation 2009; 88:1349-1359.